Home › Companies › MOONLAKE IMMUNOTHERAPEUTICS › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2024: 4 items on MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed June 6, 2024: 2 elected · 2 passed (calculated).
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore MOONLAKE IMMUNOTHERAPEUTICS in the interactive database Compare manager voting policies
These tallies are MOONLAKE IMMUNOTHERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Catherine Moukheibir | 50,398,781 | -- | -- | 4,335,564 | 4,241,512 | 92% | Elected | — |
| Elect Director: Dr. Ramnik Xavier | 53,899,047 | -- | -- | 835,298 | 4,241,512 | 98% | Elected | — |
| 2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor | 52,568,361 | 4,220 | 6,403,276 | -- | 0 | 99.9% | Passed (calculated) | — |
| 3. Advisory Vote on Executive Compensation | 54,721,123 | 5,234 | 7,988 | -- | 4,241,512 | 99.9% | Passed (calculated) | — |
Source: MOONLAKE IMMUNOTHERAPEUTICS, Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
123 asset managers disclosed a vote on at least one MOONLAKE IMMUNOTHERAPEUTICS item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of MOONLAKE IMMUNOTHERAPEUTICS’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Catherine Moukheibir
MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: Catherine Moukheibir”): 50,398,781 for, 4,335,564 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected, a frequency of one year received the plurality of votes cast on Proposal 4 and the other proposals voted on were approved.”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 2,417,042 | 0 | 0 | 0 | For |
| Fidelity | 2,316,557 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 0 | 0 | 548,604 | Withhold |
| Federated Hermes | 411,035 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 405,159 | 0 | 0 | 0 | For |
| AllianceBernstein | 339,802 | 0 | 0 | 0 | For |
| BlackRock | 252,865 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,803 | 0 | 0 | 0 | For |
| TIAA | 166,939 | 0 | 0 | 0 | For |
| Equitable | 86,518 | 0 | 0 | 0 | For |
| Vanguard | 75,958 | 0 | 0 | 0 | For |
| Principal | 71,490 | 0 | 0 | 0 | For |
| Victory Capital | 58,371 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 47,487 | 0 | 0 | 0 | For |
| John Hancock | 41,526 | 0 | 0 | 0 | For |
| Northwestern Mutual | 31,128 | 0 | 0 | 0 | For |
| ALGER PORTFOLIOS | 0 | 0 | 0 | 30,605 | Withhold |
| Lord Abbett | 26,171 | 0 | 0 | 0 | For |
| Harbor Funds II | 25,757 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 24,817 | Withhold |
| Jackson National | 24,311 | 0 | 0 | 0 | For |
| State Street | 23,232 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 23,109 | 0 | 0 | 0 | For |
| AMG FUNDS | 16,500 | 0 | 0 | 0 | For |
| Prudential/PGIM | 16,260 | 0 | 0 | 0 | For |
Fund voting reports, all 44 managers: 7,139,518 for, 610,186 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 172,881 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 172,881 for.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Ramnik Xavier
MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: Dr. Ramnik Xavier”): 53,899,047 for, 835,298 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected, a frequency of one year received the plurality of votes cast on Proposal 4 and the other proposals voted on were approved.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 2,417,042 | 0 | 0 | 0 | For |
| Fidelity | 2,316,557 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 0 | 0 | 548,604 | Withhold |
| Federated Hermes | 411,035 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 405,159 | 0 | 0 | 0 | For |
| AllianceBernstein | 339,802 | 0 | 0 | 0 | For |
| BlackRock | 252,865 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,803 | 0 | 0 | 0 | For |
| TIAA | 166,939 | 0 | 0 | 0 | For |
| Equitable | 86,518 | 0 | 0 | 0 | For |
| Vanguard | 75,958 | 0 | 0 | 0 | For |
| Principal | 71,490 | 0 | 0 | 0 | For |
| Victory Capital | 58,371 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 47,487 | 0 | 0 | 0 | For |
| John Hancock | 41,526 | 0 | 0 | 0 | For |
| Northwestern Mutual | 31,128 | 0 | 0 | 0 | For |
| ALGER PORTFOLIOS | 0 | 0 | 0 | 30,605 | Withhold |
| Lord Abbett | 26,171 | 0 | 0 | 0 | For |
| Harbor Funds II | 25,757 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 24,817 | Withhold |
| Jackson National | 24,311 | 0 | 0 | 0 | For |
| State Street | 23,232 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 23,109 | 0 | 0 | 0 | For |
| AMG FUNDS | 16,500 | 0 | 0 | 0 | For |
| Prudential/PGIM | 16,260 | 0 | 0 | 0 | For |
Fund voting reports, all 44 managers: 7,139,518 for, 610,186 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 172,881 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 172,881 for.
Combines 6 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Approval of, on an advisory basis, the compensation of the Company's named executive officers.
MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 54,721,123 for, 5,234 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 2,417,042 | 0 | 0 | 0 | For |
| Fidelity | 2,316,557 | 0 | 0 | 0 | For |
| ALGER FUNDS | 548,604 | 0 | 0 | 0 | For |
| Federated Hermes | 411,035 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 405,159 | 0 | 0 | 0 | For |
| AllianceBernstein | 339,802 | 0 | 0 | 0 | For |
| BlackRock | 252,865 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,803 | 0 | 0 | 0 | For |
| TIAA | 166,939 | 0 | 0 | 0 | For |
| Equitable | 86,518 | 0 | 0 | 0 | For |
| Vanguard | 75,958 | 0 | 0 | 0 | For |
| Principal | 71,490 | 0 | 0 | 0 | For |
| Victory Capital | 58,371 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 47,487 | 0 | 0 | 0 | For |
| John Hancock | 41,526 | 0 | 0 | 0 | For |
| Northwestern Mutual | 31,128 | 0 | 0 | 0 | For |
| ALGER PORTFOLIOS | 30,605 | 0 | 0 | 0 | For |
| Lord Abbett | 26,171 | 0 | 0 | 0 | For |
| Harbor Funds II | 25,757 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 24,817 | 0 | 0 | 0 | For |
| Jackson National | 24,311 | 0 | 0 | 0 | For |
| State Street | 23,232 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 23,109 | 0 | 0 | 0 | For |
| AMG FUNDS | 16,500 | 0 | 0 | 0 | For |
| Prudential/PGIM | 16,260 | 0 | 0 | 0 | For |
Fund voting reports, all 44 managers: 7,743,544 for, 6,160 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 21,751,284 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 6,670,937 | 0 | 0 | 0 | For |
| Fidelity | 3,577,960 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,171,019 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,580,000 | 0 | 0 | 0 | For |
| Citadel | 2,188,652 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,883,296 | 0 | 0 | 0 | For |
| AllianceBernstein | 877,446 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 853,968 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 709,545 | 0 | 0 | 0 | For |
| FRED ALGER MANAGEMENT, LLC | 662,786 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 452,580 | 0 | 0 | 0 | For |
| Federated Hermes | 433,425 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 427,557 | 0 | 0 | 0 | For |
| Finepoint Capital LP | 360,916 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 300,165 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 295,941 | 0 | 0 | 0 | For |
| 5AM Venture Management, LLC | 282,313 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 239,000 | 0 | 0 | 0 | For |
| Woodline Partners LP | 203,407 | 0 | 0 | 0 | For |
| Nuveen | 190,048 | 0 | 0 | 0 | For |
| Wellington | 177,961 | 0 | 0 | 0 | For |
| TimesSquare Capital Management, LLC | 172,881 | 0 | 0 | 0 | For |
| Victory Capital | 105,147 | 0 | 0 | 0 | For |
| Duquesne Family Office LLC | 87,500 | 0 | 0 | 0 | For |
Institutional-manager reports, all 90 managers: 49,607,201 for, 4,768 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| ALGER FUNDS | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| HARBOR FUNDS | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| Bridge Builder Trust | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| Northwestern Mutual | 0 | 0 | 0 | 0 | -- |
| ALGER PORTFOLIOS | 0 | 0 | 0 | 0 | -- |
| Lord Abbett | 0 | 0 | 0 | 0 | -- |
| Harbor Funds II | 0 | 0 | 0 | 0 | -- |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Nushares ETF Trust | 0 | 0 | 0 | 0 | -- |
| AMG FUNDS | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 44 managers: 6,160 abstained, 7,743,544 1 year. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 0 | 0 | 0 | 0 | -- |
| Cormorant Asset Management, LP | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Avoro Capital Advisors LLC | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Polar Capital Holdings Plc | 0 | 0 | 0 | 0 | -- |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 0 | 0 | 0 | 0 | -- |
| FRED ALGER MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| PICTET ASSET MANAGEMENT SA | 0 | 0 | 0 | 0 | -- |
| Finepoint Capital LP | 0 | 0 | 0 | 0 | -- |
| MPM BioImpact LLC | 0 | 0 | 0 | 0 | -- |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 0 | 0 | 0 | -- |
| 5AM Venture Management, LLC | 0 | 0 | 0 | 0 | -- |
| Candriam S.C.A. | 0 | 0 | 0 | 0 | -- |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| Wellington | 0 | 0 | 0 | 0 | -- |
| TimesSquare Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| Duquesne Family Office LLC | 0 | 0 | 0 | 0 | -- |
| Granahan Investment Management, LLC | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 86 managers: 921 for, 4,768 not voted, 47,659,381 1 year, 62,282 3 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Prior year: 100.0% for (June 7, 2023 meeting) unchanged
Description as filed by funds: Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.
MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor”): 52,568,361 for, 4,220 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 2,417,042 | 0 | 0 | 0 | For |
| Fidelity | 2,316,557 | 0 | 0 | 0 | For |
| ALGER FUNDS | 548,604 | 0 | 0 | 0 | For |
| Federated Hermes | 411,035 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 405,159 | 0 | 0 | 0 | For |
| AllianceBernstein | 339,802 | 0 | 0 | 0 | For |
| BlackRock | 252,865 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,803 | 0 | 0 | 0 | For |
| TIAA | 166,939 | 0 | 0 | 0 | For |
| Equitable | 86,518 | 0 | 0 | 0 | For |
| Vanguard | 75,958 | 0 | 0 | 0 | For |
| Principal | 71,490 | 0 | 0 | 0 | For |
| Victory Capital | 58,371 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 47,487 | 0 | 0 | 0 | For |
| John Hancock | 41,526 | 0 | 0 | 0 | For |
| Northwestern Mutual | 31,128 | 0 | 0 | 0 | For |
| ALGER PORTFOLIOS | 30,605 | 0 | 0 | 0 | For |
| Lord Abbett | 26,171 | 0 | 0 | 0 | For |
| Harbor Funds II | 25,757 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 24,817 | 0 | 0 | 0 | For |
| Jackson National | 24,311 | 0 | 0 | 0 | For |
| State Street | 23,232 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 23,109 | 0 | 0 | 0 | For |
| AMG FUNDS | 16,500 | 0 | 0 | 0 | For |
| Prudential/PGIM | 16,260 | 0 | 0 | 0 | For |
Fund voting reports, all 44 managers: 7,743,544 for, 6,160 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 172,881 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 172,881 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 62,637,212 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 3.86% |
| 2 | Fidelity | 3.70% |
| 3 | ALGER FUNDS | 0.88% |
| 4 | Federated Hermes | 0.66% |
| 5 | HARBOR FUNDS | 0.65% |
| 6 | AllianceBernstein | 0.54% |
| 7 | BlackRock | 0.40% |
| 8 | AB DISCOVERY GROWTH FUND, INC. | 0.33% |
| 9 | TIAA | 0.27% |
| 10 | Equitable | 0.14% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BVF INC/IL | 34.73% |
| 2 | Cormorant Asset Management, LP | 10.65% |
| 3 | Fidelity | 5.71% |
| 4 | T. Rowe Price | 5.06% |
| 5 | Avoro Capital Advisors LLC | 4.12% |
| 6 | Citadel | 3.49% |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.01% |
| 8 | AllianceBernstein | 1.40% |
| 9 | Polar Capital Holdings Plc | 1.36% |
| 10 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1.13% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Certain funds managed by BVF Partners L.P. | 21,751,284 | 34.73% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Entities affiliated with Bihua Chen | 8,494,151 | 13.56% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Entities affiliated with FMR LLC | 3,847,677 | 6.14% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Dr. Jorge Santos da Silva | 2,982,814 | 4.76% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Dr. Kristian Reich | 2,967,554 | 4.74% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Citadel Advisors | 2,364,933 | 3.78% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 2,135,883 | 3.41% | Form 13F, quarter ended March 31, 2024 |
| FMR (Fidelity) | 726,932 | 1.16% | Form 13F, quarter ended March 31, 2024 |
| Matthias Bodenstedt | 520,903 | 0.83% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Simon Sturge | 384,277 | 0.61% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
Percentages above are of 62,637,212 shares outstanding, as reported by MOONLAKE IMMUNOTHERAPEUTICS on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At MOONLAKE IMMUNOTHERAPEUTICS's shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 123 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 876 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval of, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 99.9% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: MOONLAKE IMMUNOTHERAPEUTICS's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MOONLAKE IMMUNOTHERAPEUTICS’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
MOONLAKE IMMUNOTHERAPEUTICS proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “MOONLAKE IMMUNOTHERAPEUTICS (MLTX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/moonlake-immunotherapeutics/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.